These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
78 related articles for article (PubMed ID: 1396071)
21. Interleukin-6 enhances the induction of human lymphokine-activated killer cells. Gallagher G; Stimson WH; Findlay J; al-Azzawi F Cancer Immunol Immunother; 1990; 31(1):49-52. PubMed ID: 2407352 [TBL] [Abstract][Full Text] [Related]
22. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor. Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733 [TBL] [Abstract][Full Text] [Related]
23. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors. Mulé JJ; Krosnick JA; Rosenberg SA J Immunol; 1989 Jan; 142(2):726-33. PubMed ID: 2783444 [TBL] [Abstract][Full Text] [Related]
24. Suppression of human monocyte function against Candida albicans by autologous IL-2-induced lymphokine-activated killer cells. Wei S; Serbousek D; McMillen S; Blanchard DK; Djeu JY J Immunol; 1991 Jan; 146(1):337-42. PubMed ID: 1898605 [TBL] [Abstract][Full Text] [Related]
25. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy. Klasa RJ; Silver HK; Kong S Cancer Res; 1990 Aug; 50(16):4906-10. PubMed ID: 2379154 [TBL] [Abstract][Full Text] [Related]
26. [Human LAK cell induction and its biological characteristics]. Wu YY Zhonghua Zhong Liu Za Zhi; 1990 Jul; 12(4):254-7. PubMed ID: 2125554 [TBL] [Abstract][Full Text] [Related]
27. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells. Saarloos MN; Khoo NK; Lala PK Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293 [TBL] [Abstract][Full Text] [Related]
28. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody]. Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634 [TBL] [Abstract][Full Text] [Related]
29. Induction of murine lymphokine-activated killer cells by recombinant IL-7. Lynch DH; Miller RE J Immunol; 1990 Sep; 145(6):1983-90. PubMed ID: 1975262 [TBL] [Abstract][Full Text] [Related]
30. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia. Gregg EO; Gregg IC; Green I Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265 [TBL] [Abstract][Full Text] [Related]
31. Exogenous interleukin 2 recruits in vitro lymphokine-activated killer activity by in vivo activated lymphocytes. Lamers HJ; Gratama JW; van Putten WL; Stoter G; Bolhuis RL Cancer Res; 1991 May; 51(9):2324-8. PubMed ID: 2015597 [TBL] [Abstract][Full Text] [Related]
32. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines. Parhar RS; Ernst P; Sheth KV; al-Sedairy ST Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260 [TBL] [Abstract][Full Text] [Related]
33. [The effect of interleukin-2, interleukin-4 and tumor necrosis factor on LAK cells activity]. Zeng Z; Si CW; Yu M Zhonghua Yi Xue Za Zhi; 1994 Apr; 74(4):235-7, 256. PubMed ID: 7922766 [TBL] [Abstract][Full Text] [Related]
34. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture. Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989 [TBL] [Abstract][Full Text] [Related]
35. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells. Atzpodien J; Gulati SC Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310 [TBL] [Abstract][Full Text] [Related]
36. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro. Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536 [TBL] [Abstract][Full Text] [Related]
37. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2. Horton SA; Oldham RK; Yannelli JR Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722 [TBL] [Abstract][Full Text] [Related]
38. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
39. Characterization of lymphokine-activated killing by human peripheral blood mononuclear cells stimulated with interleukin 2 (IL-2) analogs specific for the intermediate affinity IL-2 receptor. Heaton KM; Ju G; Morris DK; Delisio K; Bailon P; Grimm EA Cell Immunol; 1993 Mar; 147(1):167-79. PubMed ID: 8462109 [TBL] [Abstract][Full Text] [Related]